Abstract
Review question/objective The objective of this review is to synthesize the evidence from economic evaluations of the resource use and cost effectiveness of serum CA125 testing compared to transvaginal ultrasound screening for ovarian cancer. The review questions are: What are the estimates of the cost effectiveness of serum CA125 testing in females of any age compared to the use of transvaginal ultrasound testing for ovarian cancer screening? If the evidence presents a wide range of cost effectiveness measures, can any conclusions be drawn regarding the circumstances in which serum CA125 is likely to be more effective and less costly than transvaginal ultrasound as a screening test for ovarian cancer? The ultimate objective of the review is to provide information that can be used by policy makers and administrators to make evidence-informed recommendations regarding ovarian cancer screening. Inclusion criteria Types of participants The review will consider economic evaluation studies in which the participants are females of any age who have had serum CA125 or transvaginal ultrasound testing for ovarian cancer screening. Females of any age, living in any country will be considered for inclusion. Types of intervention(s) and comparator(s) The intervention of interest for this review of economic evaluation of evidence is serum CA125 screening for ovarian cancer. The comparator of interest is transvaginal ultrasonography screening method for ovarian cancer. To be included, studies must have estimated the resource use/uses relative to the benefits/effectiveness of the serum CA125 screening method compared to the transvaginal ultrasound screening test for ovarian cancer. The review will consider all economic evaluations that have focused on the two screening methods (serum CA125 and transvaginal ultrasound) regardless of the perspective (societal, individual/patient, health system). The review will exclude studies using serum CA125 testing as a marker for tumor or disease progression. Types of outcomes This review will consider studies that include cost utility or/and cost benefit or/and cost effectiveness outcome measures for the intervention (Serum CA125) and comparator (transvaginal sonogram).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JBI Database of Systematic Reviews and Implementation Reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
